{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:17:51Z","timestamp":1792412271213,"version":"4.4.0"},"reference-count":96,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome","award":["GALENOS project"],"award-info":[{"award-number":["GALENOS project"]}]}],"content-domain":{"domain":["wellcomeopenresearch.org"],"crossmark-restriction":false},"short-container-title":["Wellcome Open Res"],"abstract":"<ns3:p>Background Trace amine-associated receptor 1 (TAAR1) agonism shows promise for treating psychosis, prompting us to synthesise data from human and non-human studies. Methods We co-produced a living systematic review of controlled studies examining TAAR1 agonists in individuals (with or without psychosis\/schizophrenia) and relevant animal models. Two independent reviewers identified studies in multiple electronic databases (until 17.11.2023), extracted data, and assessed risk of bias. Primary outcomes were standardised mean differences (SMD) for overall symptoms in human studies and hyperlocomotion in animal models. We also examined adverse events and neurotransmitter signalling. We synthesised data with random-effects meta-analyses. Results Nine randomised trials provided data for two TAAR1 agonists (ulotaront and ralmitaront), and 15 animal studies for 10 TAAR1 agonists. Ulotaront and ralmitaront demonstrated few differences compared to placebo in improving overall symptoms in adults with acute schizophrenia (N=4 studies, n=1291 participants; SMD=0.15, 95%CI: -0.05, 0.34), and ralmitaront was less efficacious than risperidone (N=1, n=156, SMD=-0.53, 95%CI: -0.86, -0.20). Large placebo response was observed in ulotaront phase-III trials. Limited evidence suggested a relatively benign side-effect profile for TAAR1 agonists, although nausea and sedation were common after a single dose of ulotaront. In animal studies, TAAR1 agonists improved hyperlocomotion compared to control (N=13 studies, k=41 experiments, SMD=1.01, 95%CI: 0.74, 1.27), but seemed less efficacious compared to dopamine D2 receptor antagonists (N=4, k=7, SMD=-0.62, 95%CI: -1.32, 0.08). Limited human and animal data indicated that TAAR1 agonists may regulate presynaptic dopaminergic signalling. Conclusions TAAR1 agonists may be less efficacious than dopamine D2 receptor antagonists already licensed for schizophrenia. The results are preliminary due to the limited number of drugs examined, lack of longer-term data, publication bias, and assay sensitivity concerns in trials associated with large placebo response. Considering their unique mechanism of action, relatively benign side-effect profile and ongoing drug development, further research is warranted. Registration PROSPERO-ID:CRD42023451628.<\/ns3:p>","DOI":"10.12688\/wellcomeopenres.21302.1","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T10:30:06Z","timestamp":1712831406000},"page":"182","update-policy":"https:\/\/doi.org\/10.12688\/wellcomeopenres.crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6196-3308","authenticated-orcid":false,"given":"Virginia","family":"Chiocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-9839","authenticated-orcid":false,"given":"Malcolm R.","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5772-2475","authenticated-orcid":false,"given":"Ava","family":"Homiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9248-2954","authenticated-orcid":false,"given":"Francesca","family":"Tinsdeall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4324","authenticated-orcid":false,"given":"Claire","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4855-7911","authenticated-orcid":false,"given":"Fiona J.","family":"Ramage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7312-8676","authenticated-orcid":false,"given":"Jaycee","family":"Kennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Maksym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Rutigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke J.","family":"Vano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-0832","authenticated-orcid":false,"given":"Edoardo G.","family":"Ostinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Stansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Dehdarirad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian Omari","family":"Juma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-256X","authenticated-orcid":false,"given":"Simonne","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4510-6736","authenticated-orcid":false,"given":"Ouma","family":"Simple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-1323","authenticated-orcid":false,"given":"Olufisayo","family":"Elugbadebo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomy","family":"Tonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Mantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver D.","family":"Howes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2159-3776","authenticated-orcid":false,"given":"Toshi A.","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7865-5533","authenticated-orcid":false,"given":"Lea","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian H.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-4923","authenticated-orcid":false,"given":"Janna","family":"Hastings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-4190","authenticated-orcid":false,"given":"James","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-6378","authenticated-orcid":false,"given":"Susan","family":"Michie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3282-8502","authenticated-orcid":false,"given":"Emily S.","family":"Sena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Seedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"939-51","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.","volume":"394","author":"M Huhn","year":"2019","journal-title":"Lancet."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"824-36","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis.","volume":"399","author":"J Schneider-Thoma","year":"2022","journal-title":"Lancet."},{"key":"ref-3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia.","volume":"80","author":"J Kane","year":"2019","journal-title":"J Clin Psychiatry."},{"key":"ref-4","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01904-2","article-title":"Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics.","volume":"12","author":"D Spark","year":"2022","journal-title":"Transl Psychiatry."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"57-83","DOI":"10.1016\/j.jpsychires.2018.07.006","article-title":"The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review.","volume":"108","author":"R Girgis","year":"2019","journal-title":"J Psychiatr Res."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"60-74","DOI":"10.1016\/j.tins.2022.10.010","article-title":"Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders.","volume":"46","author":"E Halff","year":"2023","journal-title":"Trends Neurosci."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1497-506","DOI":"10.1056\/NEJMoa1911772","article-title":"A Non-D2-Receptor-Binding drug for the treatment of schizophrenia.","volume":"382","author":"K Koblan","year":"2020","journal-title":"N Engl J Med."},{"key":"ref-8","article-title":"Sumitomo Pharma and Otsuka announce topline results from phase 3 DIAMOND 1 and DIAMOND 2 clinical studies evaluating ulotaront in schizophrenia.","year":"2023"},{"key":"ref-9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413185","article-title":"Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies.","volume":"22","author":"N Dedic","year":"2021","journal-title":"Int J Mol Sci."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"5347-62","DOI":"10.1016\/j.cell.2023.10.014","article-title":"Structural and signaling mechanisms of TAAR1 enabled preferential agonist design.","volume":"186","author":"P Shang","year":"2023","journal-title":"Cell."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"4234-4249","DOI":"10.1021\/acs.jmedchem.4c00195","article-title":"Structure-based design of novel G-Protein-Coupled receptor TAAR1 agonists as potential antipsychotic drug candidates.","volume":"67","author":"Z Zhou","year":"2024","journal-title":"J Med Chem."},{"key":"ref-12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300759","article-title":"New living evidence resource of human and non-human studies for early intervention and research prioritisation in anxiety, depression and psychosis.","volume":"26","author":"A Cipriani","year":"2023","journal-title":"BMJ Ment Health."},{"key":"ref-13","article-title":"Humanising Health Care: the emergence of experiential practice and leadership in mental health services.","author":"D Gilbert","year":"2022"},{"key":"ref-14","article-title":"GALENOS involvement of people with lived experience in living systematic reviews.","author":"R Morley","year":"2023"},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"M Page","year":"2021","journal-title":"BMJ."},{"key":"ref-16","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews.","volume":"10","author":"M Rethlefsen","year":"2021","journal-title":"Syst Rev."},{"key":"ref-17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j3453","article-title":"GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research.","volume":"358","author":"S Staniszewska","year":"2017","journal-title":"BMJ."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.12688\/wellcomeopenres.19866.1","article-title":"Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies [version 1; peer review: 1 approved].","volume":"8","author":"S Siafis","year":"2023","journal-title":"Wellcome Open Res."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"261-76","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia.","volume":"13","author":"S Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"860-76","DOI":"10.1016\/S2215-0366(23)00262-6","article-title":"Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development.","volume":"10","author":"T Pillinger","year":"2023","journal-title":"Lancet Psychiatry."},{"key":"ref-21","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","article-title":"Cochrane handbook for systematic reviews of interventions.","author":"J Higgins","year":"2019"},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"179-96","DOI":"10.1016\/j.neuron.2006.09.023","article-title":"Modeling madness in mice: one piece at a time.","volume":"52","author":"P Arguello","year":"2006","journal-title":"Neuron."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"S132-S9","DOI":"10.1590\/1516-4446-2013-1164","article-title":"Animal models for predicting the efficacy and side effects of antipsychotic drugs.","volume":"35 Suppl 2","author":"P Gobira","year":"2013","journal-title":"Braz J Psychiatry."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"791-806","DOI":"10.1080\/17460441.2021.1877657","article-title":"Innovative screening models for the discovery of new schizophrenia drug therapies: an integrated approach.","volume":"16","author":"M Sotiropoulos","year":"2021","journal-title":"Expert Opin Drug Discov."},{"key":"ref-25","article-title":"Improving our understanding of the in vivo modelling of psychotic disorders: a systematic review and meta-analysis.","author":"Z Bahor","year":"2018"},{"key":"ref-26","article-title":"EPPI-Reviewer 4.0: software for research synthesis.","author":"J Thomas","year":"2010"},{"key":"ref-27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjos-2020-100103","article-title":"Development and uptake of an online systematic review platform: the early years of the CAMARADES systematic review facility (SyRF).","volume":"5","author":"Z Bahor","year":"2021","journal-title":"BMJ Open Sci."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"140-9","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues.","volume":"31","author":"D Elbourne","year":"2002","journal-title":"Int J Epidemiol."},{"key":"ref-29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"J Sterne","year":"2019","journal-title":"BMJ."},{"key":"ref-30","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies.","volume":"14","author":"C Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol."},{"key":"ref-31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000411","article-title":"Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0.","volume":"18","author":"N Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"ref-32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.105016","article-title":"Advanced methods and implementations for the meta-analyses of animal models: Current practices and future recommendations.","volume":"146","author":"Y Yang","year":"2023","journal-title":"Neurosci Biobehav Rev."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1-48","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"W Viechtbauer","year":"2010","journal-title":"J Stat Softw."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"425-38","DOI":"10.1007\/s11121-021-01246-3","article-title":"Meta-analysis with robust variance estimation: expanding the range of working models.","volume":"23","author":"J Pustejovsky","year":"2022","journal-title":"Prev Sci."},{"key":"ref-35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076754","article-title":"ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis.","volume":"383","author":"M Page","year":"2023","journal-title":"BMJ."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"629-34","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"M Egger","year":"1997","journal-title":"BMJ."},{"key":"ref-37","article-title":"R: a language and environment for statistical computing.","year":"2013"},{"key":"ref-38","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis.","volume":"18","author":"N Haddaway","year":"2022","journal-title":"Campbell Syst Rev."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"55-61","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments.","volume":"12","author":"L McGuinness","year":"2021","journal-title":"Res Synth Methods."},{"key":"ref-40","doi-asserted-by":"publisher","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse.","volume":"4","author":"H Wickham","year":"2019","journal-title":"J Open Source Softw."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"153-60","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial.","volume":"22","author":"S Balduzzi","year":"2019","journal-title":"Evid Based Ment Health."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"2003-10","DOI":"10.1111\/2041-210X.14152","article-title":"orchaRd 2.0: An R package for visualising meta-analyses with orchard plots.","volume":"14","author":"S Nakagawa","year":"2023","journal-title":"Methods Ecol Evol."},{"key":"ref-43","article-title":"galenos-project\/LSR3_taar1_H: LSR3_taar1_Human_v1.0 (LSR3_taar1_Human_v1.0).","author":"S Siafis","year":"2024","journal-title":"Zenodo."},{"key":"ref-44","article-title":"galenos-project\/LSR3_taar1_A: LSR3_taar1_Animal_v1.0 (LSR3_taar1_Animal_v1.0).","author":"V maclomaclee, ftinsdeall, Chiocchia","year":"2024","journal-title":"Zenodo."},{"key":"ref-45","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200175","article-title":"Ulotaront, a Trace Amine-Associated Receptor 1\/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.","volume":"13","author":"S Isaacson","year":"2023","journal-title":"Neurol Clin Pract."},{"key":"ref-46","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-023-00385-6","article-title":"Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.","volume":"9","author":"F Perini","year":"2023","journal-title":"Schizophrenia (Heidelb)."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"202-11","DOI":"10.1016\/j.sleep.2023.04.019","article-title":"A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.","volume":"107","author":"S Szabo","year":"2023","journal-title":"Sleep Med."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"1063-74","DOI":"10.1111\/cts.13512","article-title":"A randomized, single-dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia.","volume":"16","author":"H Tsukada","year":"2023","journal-title":"Clin Transl Sci."},{"key":"ref-49","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01331-9","article-title":"Effect of TAAR1\/5-HT1A agonist SEP-363856 on REM sleep in humans.","volume":"11","author":"S Hopkins","year":"2021","journal-title":"Transl Psychiatry."},{"key":"ref-50","article-title":"NCT04072354: a clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia.","year":"2023"},{"key":"ref-51","article-title":"NCT04092686: a clinical trial that will study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia.","year":"2023"},{"key":"ref-52","article-title":"NCT04512066: a trial of the efficacy and the safety of RO6889450 (Ralmitaront) vs placebo in patients with an acute exacerbation of schizophrenia or schizoaffective disorder.","year":"2022"},{"key":"ref-53","article-title":"NCT04038957: a clinical study to investigate the effect of an investigational drug as an added medication to an antipsychotic, in adults with schizophrenia, as measured Positron Emission Tomography (PET) imaging.","year":"2023"},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"211-354","DOI":"10.1038\/s41386-023-01756-4","article-title":"ACNP 62nd Annual Meeting: Poster Abstracts P251 - P500.","volume":"48","year":"2023","journal-title":"Neuropsychopharmacology."},{"key":"ref-55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084119","article-title":"Towards novel treatments for schizophrenia: molecular and behavioural signatures of the psychotropic agent SEP-363856.","volume":"22","author":"V Begni","year":"2021","journal-title":"Int J Mol Sci."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fpsyt.2018.00043","article-title":"Behavioral phenotyping of dopamine transporter knockout rats: compulsive traits, motor stereotypies, and anhedonia.","volume":"9","author":"S Cinque","year":"2018","journal-title":"Front Psychiatry."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"1-14","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action.","volume":"371","author":"N Dedic","year":"2019","journal-title":"J Pharmacol Exp Ther."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"5244-8","DOI":"10.1016\/j.bmcl.2012.06.060","article-title":"Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012.","volume":"22","author":"G Galley","year":"2012","journal-title":"Bioorg Med Chem Lett."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"2562-76","DOI":"10.1038\/s41380-020-0740-6","article-title":"Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine.","volume":"26","author":"M Kokkinou","year":"2021","journal-title":"Mol Psychiatry."},{"key":"ref-60","doi-asserted-by":"publisher","DOI":"10.3390\/biom12111650","article-title":"Discovery of Trace Amine Associated Receptor 1 (TAAR1) Agonist 2-(5-(4'-Chloro-[1,1'-biphenyl]-4-yl)-4 H-1,2,4-triazol-3-yl)ethan-1-amine (LK00764) for the treatment of psychotic disorders.","volume":"12","author":"M Krasavin","year":"2022","journal-title":"Biomolecules."},{"key":"ref-61","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911579","article-title":"Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)- N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the treatment of psychotic disorders.","volume":"23","author":"M Krasavin","year":"2022","journal-title":"Int J Mol Sci."},{"key":"ref-62","doi-asserted-by":"publisher","first-page":"1959-72","DOI":"10.1523\/JNEUROSCI.1931-17.2018","article-title":"Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats.","volume":"38","author":"D Leo","year":"2018","journal-title":"J Neurosci."},{"key":"ref-63","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082550","article-title":"Effect of co-treatment of olanzapine with SEP-363856 in mice models of schizophrenia.","volume":"27","author":"L Liang","year":"2022","journal-title":"Molecules."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"2580-92","DOI":"10.1038\/npp.2012.109","article-title":"Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine.","volume":"37","author":"F Revel","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"934-42","DOI":"10.1016\/j.biopsych.2012.05.014","article-title":"Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.","volume":"72","author":"F Revel","year":"2012","journal-title":"Biol Psychiatry."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"8485-90","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.","volume":"108","author":"F Revel","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1161964","article-title":"Biological evaluation and in silico studies of novel compounds as potent TAAR1 agonists that could be used in schizophrenia treatment.","volume":"14","author":"Y Wang","year":"2023","journal-title":"Front Pharmacol."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"2319-29","DOI":"10.1038\/s41386-022-01421-2","article-title":"TAAR1 dependent and independent actions of the potential antipsychotic and dual TAAR1\/5-HT1A receptor agonist SEP-363856.","volume":"47","author":"M Saarinen","year":"2022","journal-title":"Neuropsychopharmacology."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"543-56","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.","volume":"18","author":"F Revel","year":"2013","journal-title":"Mol Psychiatry."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"401-415","DOI":"10.1080\/13543784.2023.2206559","article-title":"Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.","volume":"32","author":"G Le","year":"2023","journal-title":"Expert Opin Investig Drugs."},{"key":"ref-71","doi-asserted-by":"publisher","first-page":"1279-90","DOI":"10.1080\/13543784.2022.2158811","article-title":"Ulotaront: a TAAR1\/5-HT1A agonist in clinical development for the treatment of schizophrenia.","volume":"31","author":"M H\u00f8jlund","year":"2022","journal-title":"Expert Opin Investig Drugs."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"1543-56","DOI":"10.1007\/s00406-023-01580-3","article-title":"Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.","volume":"273","author":"E Achtyes","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"ref-73","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071977","article-title":"Unlocking the therapeutic potential of ulotaront as a trace amine-associated receptor 1 agonist for neuropsychiatric disorders.","volume":"11","author":"S Kuvarzin","year":"2023","journal-title":"Biomedicines."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"659-61","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited.","volume":"22","author":"S Reagan-Shaw","year":"2008","journal-title":"Faseb J."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"501-13","DOI":"10.1016\/j.biopsych.2022.06.017","article-title":"Integrating the neurodevelopmental and dopamine hypotheses of schizophrenia and the role of cortical excitation-inhibition balance.","volume":"92","author":"O Howes","year":"2022","journal-title":"Biol Psychiatry."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"79-87","DOI":"10.1016\/j.biopsych.2018.07.003","article-title":"The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: a positron emission tomography study.","volume":"85","author":"S Jauhar","year":"2019","journal-title":"Biol Psychiatry."},{"key":"ref-77","doi-asserted-by":"publisher","first-page":"776-86","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment.","volume":"69","author":"O Howes","year":"2012","journal-title":"Arch Gen Psychiatry."},{"key":"ref-78","doi-asserted-by":"publisher","first-page":"88-94","DOI":"10.1038\/s41380-021-01250-7","article-title":"Binding of SEP-363856 within TAAR1 and the 5HT1A receptor: implications for the design of novel antipsychotic drugs.","volume":"27","author":"P Nair","year":"2022","journal-title":"Mol Psychiatry."},{"key":"ref-79","doi-asserted-by":"publisher","first-page":"663-71","DOI":"10.1038\/s41586-023-06775-1","article-title":"Recognition of methamphetamine and other amines by trace amine receptor TAAR1.","volume":"624","author":"H Liu","year":"2023","journal-title":"Nature."},{"key":"ref-80","doi-asserted-by":"publisher","first-page":"672-81","DOI":"10.1038\/s41586-023-06804-z","article-title":"Ligand recognition and G-protein coupling of trace amine receptor TAAR1.","volume":"624","author":"Z Xu","year":"2023","journal-title":"Nature."},{"key":"ref-81","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02466-z","article-title":"Newly identified structures of trace-amine associated receptor-1 (TAAR1) will aid discovery of next generation neuropsychiatric drugs.","author":"P Nair","year":"2024","journal-title":"Mol Psychiatry."},{"key":"ref-82","article-title":"NCT03669640: a study to assess the effects of RO6889450 (Ralmitaront) in participants with schizophrenia or schizoaffective disorder and negative symptoms","year":"2022"},{"key":"ref-83","article-title":"NCT04115319: a study of the long-term safety and tolerability of an investigational drug in people with schizophrenia.","year":"2022"},{"key":"ref-84","doi-asserted-by":"publisher","first-page":"773-84","DOI":"10.1042\/CS20220494","article-title":"Systematic online living evidence summaries: emerging tools to accelerate evidence synthesis.","volume":"137","author":"K Hair","year":"2023","journal-title":"Clin Sci (Lond)."},{"key":"ref-85","article-title":"Psychosis-SOLES.","author":"S Smith","year":"2024"},{"key":"ref-86","doi-asserted-by":"publisher","first-page":"40","DOI":"10.12688\/wellcomeopenres.20701.1","article-title":"Developing the mental health ontology: protocol for a step-wise method to develop an ontology for the mental health domain as part of the GALENOS project [version 1; peer review: awaiting peer review].","volume":"9","author":"P Schenk","year":"2024","journal-title":"Wellcome Open Res."},{"key":"ref-87","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-021-00190-z","article-title":"Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.","volume":"7","author":"C Correll","year":"2021","journal-title":"NPJ Schizophr."},{"key":"ref-88","doi-asserted-by":"publisher","first-page":"190-5","DOI":"10.1016\/j.schres.2017.02.020","article-title":"Possible role of rare variants in Trace amine associated receptor 1 in schizophrenia.","volume":"189","author":"J John","year":"2017","journal-title":"Schizophr Res."},{"key":"ref-89","doi-asserted-by":"publisher","first-page":"374-381","DOI":"10.1093\/schbul\/sbad148","article-title":"Up-regulation of the Trace Amine Receptor, TAAR-1, in the prefrontal cortex of individuals affected by schizophrenia.","volume":"50","author":"T Imbriglio","year":"2023","journal-title":"Schizophr Bull."},{"key":"ref-90","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3389\/fphar.2019.01027","article-title":"Non-functional trace amine-associated receptor 1 variants in patients with mental disorders.","volume":"10","author":"G Rutigliano","year":"2019","journal-title":"Front Pharmacol."},{"key":"ref-91","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.101883","article-title":"TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.","volume":"80","author":"N Dedic","year":"2024","journal-title":"Mol Metab."},{"key":"ref-92","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01295-w","article-title":"Quality assessment tools used in systematic reviews of in vitro studies: a systematic review.","volume":"21","author":"L Tran","year":"2021","journal-title":"BMC Med Res Methodol."},{"key":"ref-93","doi-asserted-by":"publisher","first-page":"181-93","DOI":"10.1042\/CS20220594","article-title":"Screening for in vitro systematic reviews: a comparison of screening methods and training of a machine learning classifier.","volume":"137","author":"E Wilson","year":"2023","journal-title":"Clin Sci (Lond)."},{"key":"ref-94","doi-asserted-by":"publisher","first-page":"560-79","DOI":"10.1038\/nrd3649","article-title":"Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.","volume":"11","author":"J Pratt","year":"2012","journal-title":"Nat Rev Drug Discov."},{"key":"ref-95","doi-asserted-by":"publisher","first-page":"1162-94","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia.","volume":"164","author":"C Jones","year":"2011","journal-title":"Br J Pharmacol."},{"key":"ref-96","article-title":"Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.","author":"S Siafis","year":"2024"}],"container-title":["Wellcome Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T13:35:14Z","timestamp":1752240914000},"score":1,"resource":{"primary":{"URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":96,"URL":"https:\/\/doi.org\/10.12688\/wellcomeopenres.21302.1","relation":{"has-review":[{"id-type":"doi","id":"10.21956\/wellcomeopenres.23562.r85389","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.23562.r80883","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.23562.r85393","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.23562.r80883","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.23562.r85393","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/wellcomeopenres.23562.r85389","asserted-by":"object"}]},"ISSN":["2398-502X"],"issn-type":[{"value":"2398-502X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]},"assertion":[{"value":"Indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/wellcomeopenres.23562.r85389, Keiko Ikemoto, The University of Tokyo, Tokyo, 20 Jun 2024, version 1, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1#referee-response-85389","order":0,"name":"referee-response-85389","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/wellcomeopenres.23562.r80883, Pramod Nair, Flinders University, Adelaide, South Australia, 17 Jul 2024, version 1, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1#referee-response-80883","order":1,"name":"referee-response-80883","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/wellcomeopenres.23562.r85393, Gavin P Reynolds, Sheffield Hallam University, Sheffield, England, 19 Jul 2024, version 1, indexed","URL":"https:\/\/wellcomeopenresearch.org\/articles\/9-182\/v1#referee-response-85393","order":2,"name":"referee-response-85393","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"Many of the authors are part of the GALENOS project, which is funded by Wellcome, a global charitable foundation. The funders had no role in the study design, data collection and analysis, or the preparation of the manuscript. The German Centre for Mental Health (Das Deutsche Zentrum f\u00fcr Psychische Gesundheit, DZPG) is funded by the Federal Ministry of Education and Research (grant number: 01EE2303B). Dr Howes acknowledged funding by Medical Research Council-UK (MC_U120097115; MR\/W005557\/1 and MR\/V013734\/1), and Wellcome Trust (no. 094849\/Z\/10\/Z) to Dr Howes and the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. Andrea Cipriani is supported by the National Institute for Health Research (NIHR) Oxford Cognitive Health Clinical Research Facility, by an NIHR Research Professorship (grant RP-2017-08-ST2-006), by the NIHR Oxford and Thames Valley Applied Research Collaboration, by the NIHR Oxford Health Biomedical Research Centre (grant NIHR203316). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health.","order":3,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}